GlassScriptPhysician profile
Tigidankay Kamara
NPI 1851750004
$993.13
in general payments reported to CMS, 2019-2025
12 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $194 · 2024: $155 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.20 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $219.08 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $155.25 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $79.62 | 2022-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $58.02 | 2025 | Uzedy |
| Luye Pharma (USA) LTD. | $29.01 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $26.62 | 2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.66 | 2023 | |
| Sunovion Pharmaceuticals INC. | $19.88 | 2022 | |
| Tris Pharma INC | $19.47 | 2025 | Dyanavel Xr |
| Alkermes, INC. | $17.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tigidankay Kamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.